Show simple item record

dc.contributor.advisorRubiano Forero, Wilson 
dc.contributor.advisorDe la Peña, Jairo 
dc.contributor.advisorRamírez-Clavijo, Sandra 
dc.contributor.advisorAguilera Otalvaro, Paula Andrea 
dc.contributor.advisorVillaveces, Mariana 
dc.creatorMonroy Muñoz, Ricardo 
dc.date.accessioned2018-07-30T14:42:46Z
dc.date.available2018-07-30T14:42:46Z
dc.date.created2018-07-11
dc.date.issued2018
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/18230
dc.descriptionIntroducción: La enfermedad de Paget extramamaria EPEM es una entidad poco común de la piel, con un cuadro clínico insidioso pero agresivo por su gran compromiso loco regional y potencial para producir metástasis e incluso la muerte. El HER2 es un biomarcador de interés por sus implicaciones clínicas en el diagnóstico, evolución y pronóstico de la enfermedad. El presente estudio propone conocer la evidencia relacionada con el comportamiento de este biomarcador en la enfermedad de Paget extramamaria. Metodología: Revisión sistemática de literatura con un componente meta-analítico en el cual se extrajo la evidencia sobre el comportamiento del HER2 en pacientes con EPEM, siguiendo el contenido de diferentes artículos publicados en las principales base de datos (Medline, Embase, Cochrane, Pubmed, Google Schoolar, Science Direct, tripdatabase) sin límite de tiempo en las publicaciones. Resultados: De 147 artículos encontrados sobre el tema, 38 cumplieron criterios para su inclusión, 692 pacientes en total, 51.1% de género masculino. La proteína HER2 se sobreexpresó en el 42.77% de los casos de EPEM extramamaria y la amplificación del gen ERBB2 fue positiva en el 11.1% de los casos. La invasión dérmica se presentó en el 87.2% de los casos mientras que la metástasis regional y recurrencia posterior a tratamiento se presentó en un 76.8% y 93.9% respectivamente. La asociación entre Her-2 y la EPEM fue significativa (p <0.001). Discusión: Existe sobrexpresión y/o amplificación del HER2 en la EPEM con un porcentaje de positividad objetivo de 42%, por tanto, la terapia con terapias blanco anti-HER2 debe considerarse como una novedosa estrategia terapéutica en casos seleccionados con positividad para este marcador.
dc.description.abstractBackround: Paget's disease extramammary EPEM is an uncommon entity of the skin, with an insidious but aggressive clinical manifestations due to its great locoregional commitment and potential to produce metastasis and even death. HER2 is a biomarker that is currently under study due to its clinical implications in the diagnosis, evolution and prognosis of the disease. The present study proposes to identify the evidence related to the behavior of this biomarker in extramammary Paget's disease. Methods: A systematic review of literature with a meta-analytical component was performed in which the evidence of the behavior of HER2 in patients with EPEM was extracted, according to different articles published in the main database (Medline, Embase, Cochrane, Pubmed, Google Schoolar, Science Direct, tripdatabase) without time limit for the publications. Results: Of 147 articles found on the subject, 38 met criteria for inclusion, (692 patients in total, 51.1% male). HER2 protein was over-expressed in 42.77% of the cases and the amplification of the ERBB2 gene was positive in 11.1%. The dermal invasion occurred in 87.2% of the cases, while the regional metastasis and recurrence after treatment occurred in 76.8% and 93.9% respectively. The association between Her-2 expressoin and the EPEM was significat (p<0.01). Discussion: There is overexpression and/or amplification of HER-2 in EPEM with a target positivity percentage of 42%, therefore therapy with anti-HER2 target therapies should be considered as a possible new therapeutic strategy in selected cases with positivity for this marker.
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.subjectEnfermedad Paget extramamaria
dc.subjectHER2
dc.subjectSobreexpresión
dc.subjectAmplificación
dc.subject.ddcGinecología & otras especialidades médicas 
dc.subject.lembEnfermedad de Paget Extramamaria
dc.subject.lembEnfermedades de la mama
dc.titleEvidencia sobre la expresión de Her-2 en la enfermedad de Paget Extramamaria
dc.typemasterThesis
dc.publisherUniversidad del Rosario
dc.creator.degreeEspecialista en Mastología
dc.publisher.programEspecialización de Mastología
dc.publisher.departmentFacultad de Medicina
dc.subject.keywordPaget extramammary disease
dc.subject.keywordHER2
dc.subject.keywordOverexpression
dc.subject.keywordAmplification
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.type.spaTrabajo de grado
dc.rights.accesoAbierto (Texto Completo)
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.source.bibliographicCitationPaget J. On disease of the mammary areola preceding cancer of the mammary gland. St Bartholomew’s Hosp Rep. 1874;10:87–9.
dc.source.bibliographicCitationCrocker H. Paget’s disease affecting the scrotum and penis. Trans Pathol Soc London. 1889;40:187–91.
dc.source.bibliographicCitationLopes Filho LL, Lopes IMRS, Lopes LRS, Enokihara MMSS, Michalany AO, Matsunaga N. Mammary and extramammary Paget’s disease. An Bras Dermatol. 2015;90(2):219–31.
dc.source.bibliographicCitationMoasser MM. The oncogene HER2; its signaling ans transforming functions ant its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469–87.
dc.source.bibliographicCitationTanaka R, Sasajima Y, Tsuda H, Namikawa K, Tsutsumida A, Otsuka F, et al. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease. Br J Dermatol. 2013;168(6):1259–66.
dc.source.bibliographicCitationSlamon DJ, Clark GM, Wong SG, Levin WJ, Ulrich A, Mcguire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (80- ). 1987;235:177–82.
dc.source.bibliographicCitationSlamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. 2001;28:13–9.
dc.source.bibliographicCitationPiccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER2 in breast cancer. Oncology. 2001;61(2):73–82.
dc.source.bibliographicCitationYeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs. 2005;23(5):391–409.
dc.source.bibliographicCitationKaram A, Berek JS, Stenson A, Rao JY, Dorigo O. HER-2/neu targeting for recurrent vulvar Paget’s disease. A case report and literature review. Gynecol Oncol. Elsevier Inc.; 2008;111(3):568–71.
dc.source.bibliographicCitationTanskanen M, Jahkola T, Asko-Seljavaara S, Jalkanen J, Isola J. HER2 oncogene amplification in extramammary Paget’s disease. Histopathology. 2003;42(6):575–9.
dc.source.bibliographicCitationTakahagi S, Noda H, Kamegashira A, Madokoro N, Hori I, Shindo H, et al. Metastatic extramammary Paget’s disease treated with paclitaxel and trastuzumab combination chemotherapy. J Dermatol. 2009;36(8):457–61.
dc.source.bibliographicCitationKanitakis J. Mammary and extramammary Paget’s disease. J Eur Acad Dermatol Venereol. 2007;5(21):581–90.
dc.source.bibliographicCitationSánchez J, Molinero J, Ferreres J, Masferrer E. Enfermedad de Paget extramamaria. Semergen. 2011;37(9):504–7.
dc.source.bibliographicCitationHatta N, Yamada M, Hirano T, Fujimoto A, Morita R. Extramammary Paget’s disease: treatment, prognostic factors and outcome in 76 patients. Br J Dermatol. 2008;158(2):313–8.
dc.source.bibliographicCitationMeissner K, Riviere A, Haupt G. Study of neu-protein expression in mammary Paget’s disease with and without underlying breast carcinoma and in extramammary Paget’s disease. Am J Pathol. 1990;137(6):1305–9.
dc.source.bibliographicCitationTanaka VD, Sanches JA, Torezan L, Niwa AB, Festa Neto C. Mammary and extramammary Paget’s disease: a study of 14 cases and the associated therapeutic difficulties. Clin (São Paulo, Brazil). 2009;64:599–606.
dc.source.bibliographicCitationYao DX, Hoda SA, Chiu A, Ying L, Rosen PP. Intraepidermal cytokeratin 7 immunoreactive cells in the non-neoplastic nipple may represent interepithelial extension of lactiferous duct cells. Histopathology. 2002;40(3):230–6.
dc.source.bibliographicCitationSmith KJ, Tuur S, Corvette D, Lupton GP, Skelton HG. Cytokeratin 7 staining in mammary and extramammary Paget’s disease. Mod Pathol. 1997;10(11):1069–74.
dc.source.bibliographicCitationKanitakis J, Thivolet J, Claudy A. p53 protein expression in mammary and extramammary Paget’s disease. Anticancer Res. 1993;13:2429–2433.
dc.source.bibliographicCitationSek P, Zawrocki A, Biernat W, Piekarski JH. HER2 molecular subtype is a dominant subtype of mammary Paget’s cells. An immunohistochemical study. Histopathology. 2010;57(4):564–71.
dc.source.bibliographicCitationShepherd V, Davidson EJ, Davies-Humphreys J. Extramammary Paget’s disease. Int J Obstet Gynaecol. 2005;112:273–9.
dc.source.bibliographicCitationLloyd J, Flanagan AM. Mammary and extramammary Paget’s disease. J Clin Pathol. 2000;53(10):742–9.
dc.source.bibliographicCitationSchettini F, Buono G, Cardalesi C, Desideri I, De Placido S, Del Mastro L. Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. Cancer Treat Rev. Elsevier Ltd; 2016;46:20–6.
dc.source.bibliographicCitationChilukuri S, Page R, Reed JA, Friedman J, Orengo I. Ectopic extramammary Paget’s disease arising on the cheek. Dermatologic Surg. 2002;28(5):430–3.
dc.source.bibliographicCitationCohen MA, Hanly A, Poulos E, Goldstein GD. Extramammary Paget’s disease presenting on the face. Dermatol Surg. 2004;30(10):1361–3.
dc.source.bibliographicCitationOnishi Y, Ohara K. Ectopic extramammary Paget’s disease affecting the upper abdomen. Br J Dermatol. 1996;134(5):958–61.
dc.source.bibliographicCitationGonzalez-Castro J, Iranzo P, Palou J. Extramammary Paget’s disease involving the external ear. Br J Dermatol. 1998;138(5):914–5.
dc.source.bibliographicCitationMckee PH, Hertogs KT. Endocervical adenocarcinoma and vulval Paget â€TM s disease : a significant association. Br J Dermatol. 1980;103(4):443–8.
dc.source.bibliographicCitationChanda JJ, Melbourne MD. Clinical reviews Extramammary Paget â€TM s disease : Prognosis and relationship to internal malignancy. J Am Acad Dermatol. American Academy of Dermatology, Inc.; 1985;13(6):1009–14.
dc.source.bibliographicCitationLiegl B, Leibl S, Gogg-Kamerer M, Tessaro B, Horn L, Moinfar F. Mammary and extramammary Paget ’ s disease : an immunohistochemical study of 83 cases. Histopathology. 2007;50:439–47.
dc.source.bibliographicCitationHendi A, Brodland DG, Zitelli JA. Extramammary Paget’s disease: Surgical treatment with Mohs micrographic surgery. J Am Acad Dermatol. 2004;51(5):767–73.
dc.source.bibliographicCitationO’connor WJ, Lim KK, Zalla MJ, Gagnot M, Otley CC, Nguyen TH, et al. Comparison of Mohs Micrographic Surgery and Wide Excision for Extramammary Paget’s Disease. Dermatologic Surg. 2003;29(7):723–7.
dc.source.bibliographicCitationBrown RS, Lankester KJ, Spittle MF. Radiotherapy or surgery in perianal paget’s disease? Br J Radiol. 2000;73(867):340.
dc.source.bibliographicCitationMoreno-Arias GA, Conill C, Sola-Casas MA, Mascaro-Galy JM, Grimalt R. Radiotherapy for in situ extramammary Paget disease of the vulva. J Dermatolog Treat. 2003;14(2):119–23.
dc.source.bibliographicCitationVereecken P, Awada A, Ghanem G, Marques da Costa C, Larsimont D, Simoens C, et al. A therapeutic approach to perianal extramammary Paget’s disease: topical imiquimod can be useful to prevent or defer surgery. Med Sci Monit. 2007;13(6):75–7.
dc.source.bibliographicCitationKariya K, Tsuji T, Schwartz RA. Trial of low-dose 5-fluorouracil/cisplatin therapy for advanced extramammary Paget’s disease. Dermatol Surg. 2004;30(2 Pt 2):341–4.
dc.source.bibliographicCitationBeleznay KM, Levesque MA, Gill S. Response to 5-fluorouracil in metastatic extramammary Paget disease of the scrotum presenting as pancytopenia and back pain. Curr Oncol. 2009;16(5):81–3.
dc.source.bibliographicCitationWatanabe Y, Hoshiai H, Ueda H, Nakai H, Obata K, Noda K. Low-dose mitomycin C, etoposide, and cisplatin for invasive vulvar Paget’s disease. Int J Gynecol Cancer. 2002;12(3):304–7.
dc.source.bibliographicCitationYamazaki N, Yamamoto A, Wada T, Ishikawa M, Moriya Y, Nakanishi Y. A case of metastatic extramammary Paget’s disease that responded to combination chemotherapy. J Dermatol. 1999;26(5):311–6.
dc.source.bibliographicCitationMochitomi Y, Sakamoto R, Gushi A, Hashiguchi T, Mera K, Matsushita S, et al. Extramammary Paget’s disease/carcinoma successfully treated with a combination chemotherapy: report of two cases. J Dermatol. 2005;32:632–7.
dc.source.bibliographicCitationWelch V, Petticrew M, Tugwell P, Moher D, Neill JO, Waters E et al. Extensión PRISMA-Equidad 2012 : guías para la escritura y la publicación de revisiones sistemáticas enfocadas en la equidad en salud. Rev Panam Salud Pública. 2013;34(4):60–8.
dc.source.bibliographicCitationWelch V, Petticrew M, Tugwell P, Moher D, Neill JO, Waters E, et al. Extensión PRISMA-Equidad 2012 : guías para la escritura y la publicación de revisiones sistemáticas enfocadas en la equidad en salud *. 2013;34(4):60–8.
dc.source.bibliographicCitationTanaka R, Sasajima Y, Tsuda H, Namikawa K, Tsutsumida A, Otsuka F YN. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease. Br J Dermatol. 2013;168–6(1259–66).
dc.source.bibliographicCitationTanaka R(1,)(2), Sasajima Y(3,)(4), Tsuda H(3,)(5), Namikawa K(6) T, A(6), Tsutsumida A(6), Fujisawa Y(7), Fujimoto M(6,)(7) YN. Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease. Clin Exp Metastasis. 2016;33(7):687–97.
dc.source.bibliographicCitationChoi YD(1), Cho NH, Park YS, Cho SH, Lee G PK. Lymphovascular and marginal invasion as useful prognostic indicators and the role of c-erbB-2 in patients with male extramammary Paget’s disease: a study of 31 patients. J Urol. 2005;174(2):561–5.
dc.identifier.doihttps://doi.org/10.48713/10336_18230
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 2.5 Colombia
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 2.5 Colombia

 

Línea de atención a estudiantes: (601) 297 0200 opción 3 y 1 I Calle 12C Nº 6-25 - Bogotá D.C. Colombia.